Tempus AI was awarded a $60.5 million five‑year contract by ARPA‑H to provide testing and CRO services for the ADAPT precision cancer therapy program, supplying whole transcriptome, exome, liquid biopsy and ctDNA assays along with data integration services. The contract positions Tempus as a core vendor for ARPA‑H’s effort to accelerate biomarker‑driven cancer trials. Tessera Therapeutics won up to $41.3 million from ARPA‑H for its EMBODY program to support in vivo CAR‑T development, funding research to advance engineering of immune cells inside the body. These awards reflect ARPA‑H’s active role in underwriting high‑risk, high‑reward approaches in precision oncology and in‑body cell therapies.